Chong Kun Dang Pharmaceutical
ckdpharm.comTotal trials
298
Active
15
Phase 3
36
Total enrollment
72,776
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 30 of 30 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Telmisartan | — | — | — | 5 | |||
| Mycophenolate mofetil | — | — | — | — | 3 | ||
| Losartan | — | — | — | — | — | 2 | |
| Mycophenolate mofetil Tablet/Capsule | — | — | — | — | — | 2 | |
| Everolimus | — | — | — | — | — | 2 | |
| empagliflozin 10mg | — | — | — | — | — | 1 | |
| Glimepiride 1mg | — | — | — | — | — | 1 | |
| Sirolimus | — | — | — | — | — | 1 | |
| EsoDuo® | — | — | — | — | — | 1 | |
| Sacubitril∙Valsartan | — | — | — | — | — | 1 | |
| Valsartan | — | — | — | — | — | 1 | |
| CKD-843 dose#1 | — | — | — | — | — | 1 | |
| CKD-843 dose#2 | — | — | — | — | — | 1 | |
| Dutasteride | — | — | — | — | — | 1 | |
| CKD-703 | — | — | — | — | — | 1 | |
| CKD-383 | — | — | — | — | — | 6 | |
| CKD-846 | — | — | — | — | — | 2 | |
| D091 | — | — | — | — | — | 2 | |
| CKD-706 | — | — | — | — | — | 1 | |
| US-Dupixent | — | — | — | — | — | 1 | |
| EU-Dupixent | — | — | — | — | — | 1 | |
| CKD-512 | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 1 | |
| CKD-215 | — | — | — | — | — | 1 | |
| D215 | — | — | — | — | — | 1 | |
| SKYRIZI | — | — | — | — | — | 1 | |
| CKD-704 | — | — | — | — | — | 1 | |
| SGLT2 inhibitor | — | — | — | — | — | 1 | |
| Thiazolidinedione | — | — | — | — | — | 1 | |
| DPP-4 inhibitor | — | — | — | — | — | 1 |
Next readouts
- 2024-08-01
- 2025-01
- 2025-10-31
- 2026-03-31
- 2026-05-27
- 2026-07
- 2026-09-30
- 2026-11-16
- 2026-12-19
- 2026-12-31
Top conditions
- Hypertension44
- Dyslipidemias15
- Hypertension and Dyslipidemia13
- Type 2 Diabetes Mellitus13
- Healthy12
- Essential Hypertension10
- Type 2 Diabetes9
- Cardiovascular Diseases8
Frequently asked questions about Chong Kun Dang Pharmaceutical
- How many clinical trials does Chong Kun Dang Pharmaceutical have on ClinicalTrials.gov?
- Chong Kun Dang Pharmaceutical is listed as the lead sponsor on 298 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Chong Kun Dang Pharmaceutical's trials are in Phase 3?
- 36 of Chong Kun Dang Pharmaceutical's trials are in Phase 3, spread across 30 active drug programs.
- What therapeutic areas does Chong Kun Dang Pharmaceutical focus on?
- Chong Kun Dang Pharmaceutical's most-studied conditions on ClinicalTrials.gov are Hypertension, Dyslipidemias, Hypertension and Dyslipidemia, Type 2 Diabetes Mellitus, Healthy.
- When are Chong Kun Dang Pharmaceutical's next clinical trial readouts?
- Chong Kun Dang Pharmaceutical has 10 upcoming primary-completion readouts tracked here; the soonest is “To Evaluate the Food Effect on Pharmacokinetic Profiles and Safety in Healthy Volunteers”, expected around 2024-08-01.